Abstract
Smoking is a well – known risk factor of many diseases. It influences the efficacy and safety of drug treatment by affecting the course of different physiological processes and modifying the metabolism of drugs. The number of researches showed decrease in efficacy of some cardiovascular drugs in smokers. Aim. To compare efficacy and safety of selective and non-selective beta–adrenoceptor blockers in smokers and nonsmokers with chronic ischemic disease. Material and Methods. Antianginal efficacy of drugs in patients of both groups was evaluated by burden tests on treadmill, effective doses of bisoprolol and propranolol were adjusted. Results. The result shows that smokers two times more often need prescription of double doses of drugs. Depressed antianginal activity of both beta-adrenoceptor blockers, especially of non-selective propranolol, in smokers was revealed. When evaluating the parameters of spirography, it was found that non-selective beta-adrenoceptor blocker propranol statistically significant decreases figures of bronchial passage, irrespective of the status of smoking. Moreover, with propranol treatment, bigger number of side effects is registered in both groups, demonstrating 30% more in smok???ers compared to nonsmokers. Conclusion. Smoking attenuates efficacy and safety of beta-blockers, especially these of non-selective ones.
Highlights
Antianginal efficacy of drugs in patients of both groups was evaluated by burden tests on treadmill, effective doses of bisoprolol and propranolol were adjusted
The result shows that smokers two times more often need prescription of double doses of drugs
When evaluating the parameters of spirography, it was found that non-selective beta-adrenoceptor blocker propranol statistically significant decreases figures of bronchial passage, irrespective of the status of smoking
Summary
Лукина Государственный научно-исследовательский центр профилактической медицины МЗ и СР РФ, Москва Курение - известный фактор риска многих заболеваний, оказывающий влияние на эффективность и безопасность лечения лекарственными препаратами путем воздействия на течение различных физиологических процессов и модификации метаболизма лекарственных средств. Сравнить эффективность и безопасность селективного и неселективного бета-адреноблокаторов у курящих и некурящих пациентов с хронической ишемической болезнью сердца. Курение снижает эффективность и безопасность лечения бета-адреноблокаторами особенно неселективными. Ключевые слова: курение, эффективность и безопасность лечения, сердечно-сосудистые препараты, пациенты с ишемической болезнью сердца, бета-адреноблокаторы. По данным других авторов никотин и СО являются наименее токсичными компонентами курения, а основное патогенное, повреждающее действие оказывают свободные радикалы сигаретного дыма [11]. Однако клинические эффекты этого фактора риска исследованы во многих работах
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
